Partner James Matthews was quoted in a CNBC article, “Mylan ‘Incorrectly’ Classified EpiPens, Shortchanging Government: Regulators,” on September 28, 2016. The article discussed allegations that Mylan is shortchanging the government on rebates for sales of EpiPen through a misclassification resulting in shortfalls of many millions of dollars in rebates owed by Mylan to the Centers for Medicare and Medicaid Services. Matthews said if Mylan is found to have misclassified EpiPens, the company runs risks beyond, “simply repaying the amount of money they should have paid.” He explained that if the Justice Department brings a successful False Claims Act case against Mylan, “they have the ability to obtain very large, potentially massive penalties … for every violation of the False Claim Act. But beyond that, they have the ability to obtain injunctive relief. The United States could disqualify, could bar Mylan, from participating in any [federal government] programs going forward.”
People
Related News
29 November 2023
In the News
Daljit Doogal Discusses Foley’s Strategic Growth and Big Law Expansion Trends in Emerging Legal Markets
Foley & Lardner LLP Chairman and CEO Daljit Doogal is quoted in The American Lawyer article, “Big Fish, Small Ponds: How Big Law Is Slowly Infiltrating Emerging Markets,” offering insight on Foley’s continued national growth and Big Law expansion trends.
28 November 2023
In the News
Kyle Faget Discusses Coverage and Reimbursement for Telehealth Services
Foley & Lardner LLP partner Kyle Faget is interviewed by Healthcare IT Today in the article, “What’s a Problem, Technology, Opportunity, or Issue That Not Enough People are Talking About?”
22 November 2023
In the News
Naikang Tsao Assesses Copyright Act’s Fair Use Defense After Warhol Foundation v. Goldsmith
Foley & Lardner LLP partner Naikang Tsao authored the Westlaw Today article, “Still too subjective: the Copyright Act’s fair use defense after Andy Warhol Foundation v. Goldsmith.”